Diabetes Care Drugs News

Related Pharmaceuticals Industry News

• June 2024: Dr. Reddy's Laboratories Ltd inked a definitive deal with Haleon PLC to buy shares of Northstar Switzerland SARL, a subsidiary of Haleon. This acquisition focuses on Haleon's global portfolio of consumer healthcare brands in the nicotine replacement therapy ("NRT") category, excluding the United States. The portfolio includes Nicotinell, an over-the-counter brand in the NRT category, boasting a significant presence in more than 30 countries, including countries of Asia.
• January 2024: Daiichi Sankyo Healthcare planned to launch an OTC version of Calonal tablets (acetaminophen), an antipyretic analgesic from Ayumi Pharmaceutical, in Japan.

• February 2024: Tyber Medical LLC received clearance for the anatomical plating system in Canada. The comprehensive portfolio previously received FDA 510(k) approval in the United States and has now been cleared through Health Canada.
• January 2023: Zimmer Biomet acquired Embody Inc., a company that focuses on soft tissue healing. Through this acquisition, Zimmer Biomet strengthens its sports medicine portfolio.

• June 2024: Moov, a prominent pain relief brand, unveiled Moov Cool, a groundbreaking product drawing inspiration from cold therapy. Harnessing the potency of menthol, this solution targets muscle and joint pain, addressing issues stemming from injuries, sprains, strains, and muscle soreness often linked to an active lifestyle.
• February 2024: Zynex Inc., a key medical technology firm, launched two innovative therapy solutions, namely the Zynex Pro Hybrid LSO and the Zynex DynaComp Cold Compression. Zynex DynaComp Cold Compression seamlessly merges cold therapy with compression, offering on-the-go recovery acceleration.
• April 2022: Zixa Strong launched an innovative oil-in-water FlashMicelle technology with a dual-action composition for fast relief from intense pain.

• June 2024: Scilex Holding Company's SP-102, also known as SEMDEXA, showed promising results in treating Lumbosacral Radicular Pain, commonly known as sciatica. In its Phase 3 trial, the treatment not only met its primary endpoints but also achieved success in key secondary measures. Patients administered with SP-102 (SEMDEXA) experienced a notable decrease in pain intensity lasting more than a month. Additionally, they exhibited statistically significant and clinically relevant enhancements in their disability index scores. Importantly, these improvements were attained with a safety profile on par with the placebo.
• February 2024: Pacira BioSciences Inc. unveiled its pivotal Phase 3 study in the Journal of Clinical Anesthesia, showcasing the safety and efficacy of EXPAREL (bupivacaine liposome injectable suspension). The study focused on its application as a single-dose sciatic nerve block in the popliteal fossa for patients undergoing bunionectomy. Notably, the results underscored EXPAREL's superior performance in pain management and opioid reduction over a 96-hour period, outshining bupivacaine HCl. These pivotal findings were crucial in securing FDA approval for this specific application.

• June 2024: Elion Therapeutics, a biotech company headquartered in New York, secured USD 81 million in funding through its Series B round. The funding is specifically earmarked for advancing its early-stage polyene anti-fungal therapy, SF001.
• January 2024: Fresenius Kabi introduced Posaconazole Injection, a generic substitute for Noxafil, for use in treating or preventing serious fungal infections in adults and children who have an increased chance of getting these infections due to a weakened immune system.

• In March 2024, Jesse Ventura introduced a cannabis edible brand. Ventura partnered with Retro Bakery, based in Columbia Heights, to manufacture THC edibles derived from hemp. 
• February 2023: Metrc reported the expansion of its contract with the State of Missouri to support the regulation of its adult-use cannabis market.

• March 2024: Santhera Pharmaceuticals launched AGAMREE (vamorolone) for treating DMD in the United States. The drug was launched by Catalyst Pharmaceuticals Inc., Santhera's commercialization partner for North America.
• February 2024: BioMarin conducted Phase 1/2, an open-label, multi-center study consisting of two parts to evaluate the safety and tolerability of BMN 351 at escalating doses in participants with DMD, with genetic mutations amenable to exon 51 skipping.

• In February 2024, gastrointestinal care startup Salvo Health closed a USD 5 million Seed Prime round led by City Light Capital and Human Ventures. The company offers a virtual care clinic for people with chronic gut issues and will use the funds to expand its reach with providers.

• In March 2024, Johnson & Johnson submitted a supplemental Biologics License Application (sBLA) to the US Food and Drug Administration (FDA) seeking approval of TREMFYA (guselkumab) for the management of adults with moderately to severely active ulcerative colitis (UC).

• February 2024: Empower Pharma agreed to purchase a facility in East Windsor, New Jersey, from Eugia US Manufacturing LLC (a wholly-owned subsidiary of Aurobindo Pharma Ltd) and enter into a contract manufacturing relationship for expanding their personalized compounded medicine.
• September 2023: LO3 Capital, a private investment firm, offered a senior subordinated debt investment to support Empower Pharmacy (Empower) with growth capital. The investment was intended to help in expanding patient access to quality, affordable, compounded medication.

• October 2022: Bausch Health Companies Inc. implemented changes to the Tabular Index for the prevention and treatment of SAD as per the Centers for Medicare & Medicaid Services (CMS) guidelines. Consequently, all relevant codes have been consolidated into a unified bundle for SAD. This modification facilitates healthcare professionals in providing a more straightforward diagnosis through an easily accessible index tab, condensing all SAD diagnoses into one simplified code: F33.
• February 2022: Granules India received approval from the United States Food and Drug Administration to market Bupropion Hydrochloride extended-release tablets in the United States to treat major depressive disorder and seasonal affective disorder.